These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Genetic linkage of autosomal dominant neovascular inflammatory vitreoretinopathy to chromosome 11q13. Stone EM; Kimura AE; Folk JC; Bennett SR; Nichols BE; Streb LM; Sheffield VC Hum Mol Genet; 1992 Dec; 1(9):685-9. PubMed ID: 1284594 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of neovascularization but not fibrosis with the fluocinolone acetonide implant in autosomal dominant neovascular inflammatory vitreoretinopathy. Tlucek PS; Folk JC; Orien JA; Stone EM; Mahajan VB Arch Ophthalmol; 2012 Nov; 130(11):1395-401. PubMed ID: 22777573 [TBL] [Abstract][Full Text] [Related]
8. Long-Term Outcomes and Risk Factors for Severe Vision Loss in Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV). Boyce TM; Whitmore SS; Varzavand K; Russell SR; Sohn EH; Folk JC; Stone EM; Han IC Am J Ophthalmol; 2022 Jan; 233():144-152. PubMed ID: 34302771 [TBL] [Abstract][Full Text] [Related]
9. Immunohistologic study of epiretinal membranes in proliferative vitreoretinopathy. Baudouin C; Fredj-Reygrobellet D; Gordon WC; Baudouin F; Peyman G; Lapalus P; Gastaud P; Bazan NG Am J Ophthalmol; 1990 Dec; 110(6):593-8. PubMed ID: 1701071 [TBL] [Abstract][Full Text] [Related]
10. Functional validation of a human CAPN5 exome variant by lentiviral transduction into mouse retina. Wert KJ; Skeie JM; Bassuk AG; Olivier AK; Tsang SH; Mahajan VB Hum Mol Genet; 2014 May; 23(10):2665-77. PubMed ID: 24381307 [TBL] [Abstract][Full Text] [Related]
11. Surgical management of fibrotic encapsulation of the fluocinolone acetonide implant in CAPN5-associated proliferative vitreoretinopathy. Tlucek PS; Folk JC; Sobol WM; Mahajan VB Clin Ophthalmol; 2013; 7():1093-8. PubMed ID: 23785231 [TBL] [Abstract][Full Text] [Related]
12. Multilaminated Vitreomacular Traction in Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy. Han IC; Critser DB; Folk JC Ophthalmol Retina; 2019 Jul; 3(7):588. PubMed ID: 31277800 [No Abstract] [Full Text] [Related]
13. The histopathology of familial exudative vitreoretinopathy. A report of two cases. Boldrey EE; Egbert P; Gass JD; Friberg T Arch Ophthalmol; 1985 Feb; 103(2):238-41. PubMed ID: 3977696 [TBL] [Abstract][Full Text] [Related]
14. Congenital retinal fold as a sign of dominant exudative vitreoretinopathy. van Nouhuys CE Albrecht Von Graefes Arch Klin Exp Ophthalmol; 1981; 217(1):55-67. PubMed ID: 6911005 [TBL] [Abstract][Full Text] [Related]
15. Lymphocytes, macrophages and HLA-DR expression in vitreal and epiretinal membranes of proliferative vitreoretinopathy. An immunohistochemical study. Tang S; Scheiffarth OF; Wildner G; Thurau SR; Lund OE Ger J Ophthalmol; 1992; 1(3-4):176-9. PubMed ID: 1483132 [TBL] [Abstract][Full Text] [Related]
16. Early-onset Neovascular Inflammatory Vitreoretinopathy Due to Two de Novo CAPN5 Mutations in Chinese Patients: A Case Series. Xia FJ; Lyu J; Zhang X; Fei P; Zhao PQ Ocul Immunol Inflamm; 2023 Nov; 31(9):1777-1784. PubMed ID: 36369866 [TBL] [Abstract][Full Text] [Related]
17. Immune response to specific molecules of the retina in proliferative vitreoretinal disorders. Grisanti S; Heimann K; Wiedemann P Graefes Arch Clin Exp Ophthalmol; 1994 May; 232(5):302-7. PubMed ID: 8045440 [TBL] [Abstract][Full Text] [Related]
18. Criswick-Schepens syndrome (familial exudative vitreoretinopathy). Study of a Colombian kindred. Nicholson DH; Galvis V Arch Ophthalmol; 1984 Oct; 102(10):1519-22. PubMed ID: 6487118 [TBL] [Abstract][Full Text] [Related]